Led by the Michael J. Fox Foundation for Parkinson’s Research (MJFF), an international group of patients, researchers, and industry leaders has proposed a framework for defining and staging Parkinson’s disease based on its underlying biology rather than by hallmark disease symptoms. Called the neuronal alpha-synuclein disease integrated…
News
Scientists have proposed a new way to classify Parkinson’s disease based on biological changes associated with the disorder. “Without looking at the biology, you can’t get answers. And without answers, we won’t have much-needed breakthroughs in Parkinson’s,” Anthony Lang, MD, a researcher at the Krembil Brain Institute in Canada,…
Centogene and The Michael J. Fox Foundation (MJFF) are teaming up on a research project to investigate genetic risk factors for Parkinson’s disease, with a particular focus on GBA gene mutations. This project’s main goal is to better understand how certain variations in the GBA gene are connected…
Before deep brain stimulation (DBS), a surgical treatment for Parkinson’s disease, made it possible for guitarist Fabio Dwyer to again play and return to his livelihood in Canada, all had seemed lost. Be it performing, composing, or teaching, Dwyer’s world was ensconced in music. He had helped…
ProMIS Neurosciences announced arriving at a lead candidate vaccine against the misfolded alpha-synuclein protein, which the company plans to develop as a treatment for Parkinson’s disease and related disorders. The potential vaccine, known as PMN400, is moving into preclinical testing in animal models of Parkinson’s. “We are…
A decade after its establishment, the Friends of Parkinson’s — a group that supports, educates, and advocates for those living with the progressive neurodegenerative disorder — is asking for donations to allow it to grow and be of greater help. Jamillah Ali-Rahman, who founded the Nevada-based nonprofit in 2014,…
Air pollution may increase the risk of Parkinson’s disease, particularly in people who are already genetically predisposed to develop the disorder, a study shows. “We discovered that individuals with elevated genetic susceptibility and heightened exposure to air pollutants faced a markedly heightened risk of [Parkinson’s],” its researchers wrote. “Therefore,…
Levodopa Cyclops, an inhaled version of levodopa that PureIMS is developing as a treatment for off episodes with Parkinson’s disease, safely delivers levodopa to the body faster than an existing inhaled formulation of the therapy. That’s according to results from a company-sponsored clinical trial (NCT06037590) comparing…
Scientists at Purdue University are advancing in lab studies multiple small molecule compounds aiming to prevent the protein aggregation associated with Parkinson’s, Alzheimer’s, and type 2 diabetes, and to safely get rid of existing clumps. Protein aggregation is the term for when proteins — usually abnormal or misfolded…
In a new approach to drug discovery, seven molecules, or “hits,” that may treat familial Parkinson’s disease were identified in the first open science competition run by the Canadian nonprofit Conscience. Launched with support from the global public-private partnership Structural Genomics Consortium (SGC) and a grant from…
Recent Posts
- Taking time for self-care is crucial as a caregiver
- Early trial data suggest GT-02287 may ease Parkinson’s symptoms
- The new year is a perfect time to reflect on unexpected gifts
- Webcams, AI track Parkinson’s progression using eye movement
- Blocking 2 proteins could slow Parkinson’s progression: Study